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Abstract 
Many mathematical models have focused on growth of a single tumor with their spreading rate 
with some have included its metastasis. Some of the earlier models focus on exponential growth 
and its shift with time on to a linear model. The Gompertzian model involves a quadratic terms 
and that limit growth. We looked into Iwata et al paper it discusses a different model and takes 
into account the growth and metastasis of a tumor population but does not look into tumor 
shrinking or chemotherapy. Our new model focuses on the extending Iwata et al model to take     
into account tumor regression, we design with a discrete tumor size model which focuses on a 
limited number of tumors and this will help us to extend the model to consider tumor size into 
continuum model. 
Cancer is the world’s deadly health killer and is the second leading cause of death in the United 
States [13]. Cancer has been found throughout history. Some evidence is also found in fossilized 
bone tumors and in human mummies and from ancient Egypt times. Cancer is largely a 
manifestation of abnormal cell growth with the potential of spreading to different parts of the 
body. They can form a new tumor, which is a group of the cells that undergoes unregulated 
growth often forming a mass or lump in certain parts of the body, it can distribute diffusely [13]. 
Untreated cancer usually causes serious illness and sometimes death. There are many signs of a 
cancer, like the formation of mass or lump growth, abnormal bleeding, weight loss, a change in 
bowl movement and so on. There are many different kinds of a cancer, like melanoma which 
kills about 8000 people in the US annually and 40000 people worldwide [14]. There are many 
causes associated with various cancers like tobacco use, obesity, poor diet, and consumption of 
alcohol and so on. Cancer productivity can also be hereditary where it can be passed from 
parents DNA [15]. It is very difficult to know exactly what could have caused any one person’s 
cancer. Cancer cells form tumors and invade other parts of the normal tissue. There are some 
cancers that rarely form tumors like leukemia where cancer cells involves the blood and blood 
forming organs and they circulate through other tissues as they grow. When cancer cells gets into 
the blood stream they can form new tumors after invading other normal tissue. This process of 
spreading is called metastasis [15]. 
  
 
Introduction 
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Cancer treatment is an ongoing research but much advancement has been made in the field in 
which a cancer patient can survive for a longer period of time. According to the American cancer 
society, in 2013 there were 1.6 million cases expected to be diagnosed whereas 580000 
Americans were projected to die of cancer this is equivalent to 1600 people per day [13]. This 
makes the cancer the second most common cause of death in the USA.  Cancer cells grow 
abnormally and out of control while invading other tissue in the body. Cancers of different types 
behave differently. Lung cancer, skin cancers are cancers where cells grow at different rates and 
there are different treatments. Thus people with cancer need treatment aimed at that kind of 
cancer.  
There are many treatments available to kill cancer cells using powerful chemicals one such 
approach to treatment is chemotherapy [15]. We focused more on Chemotherapy because it kills 
the cancer cells directly before it spreads to other parts of the body. Chemotherapy treatment was 
first developed during World War II where the soldier was exposed to mustard gas. This gas was 
found to cause toxic changes in bone marrow which develops into blood cells. During that period 
the US army found effective agents for war. Compound called nitrogen mustard was found to 
work against a cancer of the lymph nodes called lymphoma [15]. This was a good breakthrough 
because this agent served as the model for similar agents called alkylating agents that killed 
rapidly growing cancer cells by damaging their DNA. Aminopterin was another such discovery it 
blocks a critical chemical reaction needed for DNA replication [21]. Methotrexate a cancer drug 
that is commonly used today is a predecessor of Aminopterin. Since then many other drug have 
come into the market. Choriocarcinoma is a rare tumor was first cured using methotrexate. 
Chemotherapy has been very successful in treating people with cancer. Today adjuvant therapy 
is often used to treat cancer cell, adjuvant therapy is the combination of chemotherapy and 
surgery [22].  
Chemotherapy is a drug treatment that typically kills fast growing cells in body. There are some 
speculations that it also kills healthy cells in our body. Chemotherapy drugs are used to treat 
wide variety of cancers. There are many types of chemotherapy drugs available [22]. It is often 
an effective way to treat cancer but there are also many side effects that come with 
chemotherapy. Some side effects are. Nausea, Vomiting, Diarrhea, Hair loss, Loss of appetite, 
Fatigue, Fever, Mouth sores, Pain, Constipation, easy bruising.  Often doctor’s use chemotherapy 
in addition to other methods, for example chemotherapy can be used to shrink a tumor size so 
other treatments like surgery and radiation could be possible. Chemotherapy kills cancer cells 
which many relieve the signs and symptoms of cancer.  
Chemotherapy drugs are selected based on the person and cancer type. It is mostly determined 
based on the following method. 
 Type of cancer 
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 Stage of cancer 
 Overall health 
 Previous cancer treatments 
 Your goals and preferences 
 
“Chemotherapy is given in the following different ways as seen. 
 Chemotherapy infusions. Chemotherapy is most often given as an infusion into a vein 
(intravenously). The drugs can be given by inserting a tube with a needle into a vein in your 
arm or into a device in a vein in your chest. 
 Chemotherapy pills. Some chemotherapy drugs can be taken in pill or capsule form. 
 Chemotherapy shots. Chemotherapy drugs can be injected with a needle, just as you would 
receive a shot. 
 Chemotherapy creams. Creams or gels containing chemotherapy drugs can be applied to 
the skin to treat certain types of skin cancer. 
 Chemotherapy drugs used to treat one area of the body. Chemotherapy drugs can be 
given directly to one area of the body. For instance, chemotherapy drugs can be given 
directly in the abdomen (intraperitoneal chemotherapy), chest cavity (intrapleural 
chemotherapy) or central nervous system (intrathecal chemotherapy). Chemotherapy can also 
be given through the urethra into the bladder (intravesical chemotherapy). 
 Chemotherapy given directly to the cancer. Chemotherapy can be given directly to the 
cancer or, after surgery, where the cancer once was. As an example, thin disk-shaped wafers 
containing chemotherapy drugs can be placed near a tumor during surgery. The wafers break 
down over time, releasing chemotherapy drugs. Chemotherapy may also be injected into a 
vein or artery that directly feeds a tumor.” [17] 
Melanoma is the most dangerous form of skin cancer. Melanoma treatment has been the subject 
of ongoing research for long time. It is found that chemotherapy works better on small tumor as 
compared to large tumor [23]. Melanoma tumors originate in the pigment that produces 
melanocytes in the basal layer of the epidermis. Melanomas are black or brown colored pigment 
which develops during intense exposure to the UV radiation normally from sunburn [23]. 
Melanoma kills about 10,000 people annually in US. Melanoma is treated easily during early 
stages but it becomes very hard to treat once it spreads to other parts of the body. The American 
Cancer society estimates that 135,000 new cases of melanoma in the US are diagnosed in a year 
[17]. 
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According to American Cancer society 42,670 males and 31,200 women will have invasive 
melanoma in 2015 [15]. In our Mathematical models to describe the dynamics of a tumor 
population that describes the growth rate with chemotherapy and metastasis for tumors of 
different sizes. Our model is based on discrete tumor growth size.  We plan to apply it to a 
melanoma system found in the zebra fish model and to correlate it with clinical data.  
Zebra fish have several advantages to be used for cancer study. Zebra fish develops cancer which 
is quite similar to that of humans [8]. Rapid growths of tumors allow us to monitor the large 
scale transgenic and see the growth of tumor cells as it develops. There are also many advantages 
of using Zebra fish such as their skin is translucent so it lets us observe the growth of tumors and 
we can easily monitor the treatment. Another advantage of zebra fish is that a mating pair 
produces 200-300 embryos a week, which enables us to test anti-cancer drugs in thousands of 
fish at a given time. Zebra fish have a tendency to develop cancer that is histological and 
genetically similar to that of humans [9]. Vivo visualization is the main advantage of using Zebra 
fish to see cancer growth and progression at single cell resolution [2].  
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The above image shows the anatomy of a Zebra fish it can help us locate the spread of tumor 
cells. There are many positive and negative effects of using zebra fish for cancer research. Some 
of the positive effects are that in zebra fish a single adult mating pair produces 200 or more 
embryos per week which allows the screening of relevant adult phenotypes using space efficient 
embryos [8]. These fish have the same organs as relevant to the human body and have a complex 
immune system with T and B cells, macrophages and monocytes. Mosaic transgenic which is a 
process of introducing an exogenous gene into organism so that the organism will exhibit new 
property and transmit it to its offspring, can also be created at the rate of 500- 1000 animals per 
day which is very large and this stable transgenic can be found in 50% of injected animals with 
the transpose based systems [8]. Forward genetic and reverse genetics are highly stable and 
scalable. See through or transparent strains help us to monitor in the vivo imaging of tumor 
growth, migration and metastasis. Vascular endothelium, red and white blood cells, platelets and 
stroma, which are cells with transgenic lines are available. There are also numerous successes of 
chemical screening in zebra fish, which has led to clinical trials in patients with melanoma. Also 
the microinjection of human genes under tissue prompter has led to tumors that are similar to that 
of human disease. Lastly tumors in zebra fish strongly resemble human tumors at the gene 
expression and genomic levels. In addition to the positive effects there are also many negative 
effects such as the zebra fish are short lived as compared to humans [9]. Their organs are also 
simpler than their mammalian counterparts; the kidneys resemble the mesonephric rather than 
the metanephric stage. Also some of the mammalian organs are not conserved. The genome size 
is approximately one-half the size of the human genome, making comparisons outside gene 
regions difficult. The genome underwent a genome duplication event; so many genes have a 
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redundant copy, which complicates loss-of-function studies of tumor-suppressor genes. Zebra 
fish grow at 28.5°C, rather than at 37°C, and are poikilothermic, limiting studies in which 
mammalian homeostatic temperature may be important to on congenic phenotypes [9].  
BRAF gene which is the gene found in the human body that is responsible to make proteins send 
signals inside the cell and is responsible for cell growth. It was discovered that this growth is 
found to be faulty in some human cancers which has led to the discovery of drugs directly 
targeting them; they are called BRAF inhibitors. Vemurafenib and dabrafenib are two drugs 
known to treat late stage melanoma. Vemurafenib treatment reduces the cancer cell in half and 
the survival time increases by 6 months or over [6]. This drug is approved by FDA for the 
treatment of BRAF mutation. In a clinical trial conducted by the New England journal of 
medicine it was found that the patient taking Vemurafenib have the overall survival of 84% after 
6 months [6]. These drugs have the ability to interfere with the cancer cell to grow, divide, repair 
and communicate with other cells. These drugs are called targeted therapy drugs. They use small 
molecules that get into the cell and disrupt the function of the cancer cells, causing them to die. 
Some targeted therapy target receptors that are on the outside of the cell. Vemurafenib which is 
the form of target therapy target the mutated BRAF proteins (kinase) within the cancer cell [3].  
BRAF gene plays an important role in normal and cancer cells. A BRAF protein which is 
produce from this gene is a part of a chain of molecules that relay a signal and tells cells how to 
grow and divide. Mutation is the change in BRAF gene that can alters the way in which BRAF 
protein works. Instead of waiting for its turn to signal a cell to divide or grow, the BRAF protein 
is out of control and this may drive the uncontrolled growth of cancer cells. Vemurafenib targets 
these changed BRAF proteins and may slow down the growth of cancer [5].     
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The above graph shows the result from the clinical study from the Vemurafenib drug showed a 
drastic improvement in the survival rate [11].  
Although these drugs are great there are other challenges that remain in virtually every patient 
treated with these drugs.  
Many patients develop resistances to selective RAF kinase inhibitors; these resistances to RAF 
inhibitors are not understood completely. Melanoma immunotherapy has made significant 
progress to block the dense T-cell found in Melanoma tumors. CTL4 and PD1 are the T-cell 
checkpoints which prevent the immune system from attacking the tumor. Ipilimumab is a 
treatment for Melanoma that cannot be removed by surgery but spread to the other parts of the 
body, blocks CTLA4 [20]. This drug is approved by FDA and the response has been very 
positive. Nivolumab which is the generic name for a drug called Opdivo is an inhibitor for PD1. 
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This drug is also approved by FDA and the response rate has been very high. In some case it was 
found to be 79% survival rate after 2 years [10, 20].  
Our model focuses on the interaction between therapy and tumor growth. There has been a long 
history of tumor modeling. Many models have worked on a single tumor, average tumor or a 
sum of 4 or 5 largest tumors and its growth rate which was earlier assumed to be exponential. It 
was then assumed to be a linear growth in time. Molecular beam epitaxial (MBE) which is a 
class of studies done on 15 lines of cells growing into 16 different types of tumors where all cell 
colonies were found to inhibit the same cells growth. MBE dynamics are sometimes described as 
a linear growth rate where a surface diffusion of cells occurs at the growing edge. MBE 
dynamics was experimentally studied in colonies of the tumor growth [12]. These studies 
challenge the concept of exponential growth and the Gompertzian growth. It is a linear growth 
regime where the tumor growth is conceived as the competition for space between the tumor and 
the host. These models account for unbounded growth terms and add other logistical terms. 
Another Gompertzian model which cuts off the growth due to crowding and immunity leads to a 
bounded sigmoid growth shape with time [12]. A different class of differential equation models 
each term represents the rate of a specific interaction. These models focus more on how a tumor 
competes with healthy cells. It also shows that tumors nucleate better on surfaces than in bulk 
regions. Iwata et al proposed new point of view in which tumor size is continuous. It leads to a 
time dependent histogram of a primary tumor vs. tumor size [1].  
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The above figure shows the changes in the size distribution of tumors with progression of 
metastasis of a hepatocellular carcinoma. In graph a, the three different times indicated by 
different dash lines shows the cumulative number of tumors as a function of the colony size after 
the first diagnosis of primary tumor. The thick curves are theoretical cumulative distributions. 
The thin lines are the colony size distributions for the corresponding thick curves. The shape of 
tumor was assumed as spheroidal ellipsoid to calculate the volume of the tumor. A tumor of 1 
mm^3 was assumed to contain 10^6 cells. In graph b, the theoretical Gompertz growth is 
compared with the observed growth data of the primary tumor [1]. 
This model allowed one to track the growth of a primary tumor along with the generation of 
metastases. This model defines the mathematical terms and uses the numerical and asymptotic 
approaches that are most successful into analysis. Although this model takes into account tumor 
growth and metastasis generation it fails to admit the tumor shrinkage which can cause by 
chemotherapy [1]. This is the main topic of interest of cancer research and we would focus more 
into the chemotherapy term. We took Iwata et al paper into account and developed the idea of 
tumor shrinkage into our account. In order to study these effects we divided our study into two 
parts one is a discrete model where we begin by describing the tumor with discrete numbers of 
cells and reveal important interactions to be later used for continuous model [1].  
Iwata et al model uses the idea of single cell development of metastasis and forms them into 
colonies which are then subject into the Gompertzian growth rate given as  
      
Here "a" is the growth rate constant; b is the tumor size at the saturated level, g(x) is the 
Gompertzian growth rate and x represents number of cells in primary tumor at time t. The above 
equations are solved to give us the resulting equation which gives a relationship between 
numbers of cells in primary tumor as a function of time [1]. 
 
β (x) = mx^α is the colonization rate adopted which is similar to the power law function. This 
equation tells us that the rate of metastasis from a tumor with size x is proportional to the number 
of tumor cells in contact with the blood vessels [1].  
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Iwata et al then used the Gompertzian growth rate along with Laplace transformation method to 
obtain the equation for colony size distribution of metastatic tumors with cell number x at time t. 
 
The above equation was compared to the clinical data and there were some prediction made on 
the behavior of metastasis. Iwata et al model was the starting point for our research it gave us the 
basis to understand the growth rate but it fails to address the tumor shrinkage. Also the behavior 
of the colony size distribution of tumor changes after treatment such as chemotherapy, 
radiotherapy, which was not taken into account by the above model. We develop our model 
which takes all this effects into consideration [1]. 
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Mathematical Model and the Program 
Each year billions of dollars are being spent on cancer research. For instance, 5.4 billion dollars 
were spent in year 2014 just from by the government in the U.S.A.
 (4)
 Progress has been made in 
the development of new drugs and treatments for various types of cancer. However, despite huge 
spending and great amount of human resources there is still more work needs to be done 
specifically creating models of cancer tumor growth.  Wide ranges of different models have been 
used to explain cancer tumor growth. The traditional models have been only about tumor growth 
and metastasis processes in a cancer tumor. Most models are based on Gompertzian growth rate 
of a tumor. This model describes tumor growth by an exponential growth rate followed by 
slower growth rate. Here we will build up on Iwata et al’s Dynamical model. Iwata et al’s model 
focuses on metastasis process in which affected cells are spread to different parts of the body. 
Then these cells develop into secondary and tertiary small tumors. Their growth and numbers 
multiply in numbers by this process. The model assumes that colonization begins from a single 
cell and each colony has the possibility to evolve into metastasis. This process depends on the 
colony size and tumor vascularity [2].  
 
    Equation 1:                           
𝑑𝑁𝑗
𝑑𝑡
 = 𝑘1(𝑁𝑗−1⎼𝑁𝑗) + 𝑘0(𝑁𝑗+1⎼𝑁𝑗) 
                                                                Growth           Metastasis 
 
Above is a simple model for tumor growth and metastasis where 𝑁𝑗 is a population of j size 
tumor. According to Iwata et al, latest technology cannot reliable detect cancer cell colonies 
smaller than a few millimeters in size.
 (1)
 The dynamic model provided by Iwata et al and 
colleagues can be used to estimate number of colonies below delectability limit and to predict 
future behavior of metastasis.
 (1)
 Knowing how it spreads through metastasis we can analyze to 
counteract the tumor from spreading by means of immunotherapy. Medical experts measures 
tumor sizes and track them to see how sizes change over long period of time. It will also be 
useful to investigate what effects therapy will have on this model. So we will further develop on 
Iwata et al’s model to solve the equation by adding chemotherapy term. There are two types of 
models that can be considered continuum or discrete. Here we will explore and study the discrete 
model in terms of tumor size for sizes from 0 to 10
8 
cells 
(3)
 and will require a model with 
continuous tumor sizes. Then next phase will include the continuum model. Killing the affected 
cells with chemotherapy helps counteract growth. Therefore, examining the effect of different 
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variables through chemotherapy will advance our understanding of cancer.  Following is the 
mathematical model for discrete tumor size case. 
 
 
Equation 2:                
𝑑𝑁𝑗
𝑑𝑡
 = 𝑘1(𝑁𝑗−1⎼𝑁𝑗)⎼𝑓(𝑁𝑗⎼𝑁𝑗+1) + 𝑘0(𝑁𝑗+1⎼𝑁𝑗)      (j > 1) 
                                            Growth          chemotherapy     metastasis 
 
The above equation models the tumor size distribution over time. The model reflects the effects 
of metastasis and immunotherapy on tumor growth. The imbalance of cell birth and cell death 
can result in tumor growth.
 (3)
 Earlier models assumed only exponential tumor growth and not 
any immunity to growth. So there is a need to explore the other side of the story. We assume that 
process where cells break off from a parent tumor and seed new tumors somewhere else is a first 
order process. In the above equation, term Nj is a population of j size tumor. 
𝑑𝑁𝑗
𝑑𝑡
Indicates rate 
change population of j size tumor at time t. k1 describes the effective rate constant of tumor 
growth which includes the term k1 = k10 j
α
 where k10 is the pre factor of the rate of growth. 
𝑘1(𝑁𝑗−1⎼𝑁𝑗) describes the change of population of tumor size from j to j-1. Similarly, 
𝑓(𝑁𝑗⎼𝑁𝑗+1) indicates tumor death rate which scales back the size of the tumor from j+1 to j, 
where f is effective death rate containing f = f0 j
β
. This is the term that is omitted in traditional 
models. The last term on right hand side of equation 2 is a metastasis term which includes any 
affected cell break off to form new tumors in the body. Matlab code is written incorporating the 
above equation to explain tumor distribution and longtime effect of therapy.   
 
Notation Description 
j Number of cells in tumor 
t Time 
Nj Probability of selecting tumor of size j 
randomly for tumor distribution 
k1 Cell growth rate constant 
f Cell death rate constant 
k0 Cell metastasis constant 
k0’ Metastasis implantation rate 
α Factor for growth dependence on tumor size 
β Factor for death dependence on tumor size 
γ Factor for metastasis dependence on tumor 
size 
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Summary of Method 
A second order accurate Runge-Kutta type time discretization was used to solve the system of 
ODE needed to find the tumor size distribution.  The code used was originally written in the 
Matlab programming language by Professor Horacio Rotstein and Professor David Rumschitzki.  
The ODE and boundary conditions are described below. Equation 1 defines a total of jmax-2 ODE 
where jmax is the maximum tumor size allowed in the simulation.  Equations 2 and 3 define the 
boundary conditions for the system at j = 1 and j = jmax. 
𝑑𝑁𝑗
𝑑𝑡
= 𝑘1[(𝑗 − 1)
𝛼𝑁𝑗−1 − 𝑗
𝛼𝑁𝑗] + 𝑓[(𝑗 + 1)
𝛽𝑁𝑗+1 − 𝑗
𝛽𝑁𝑗] + 𝑘0[(𝑗 + 1)
𝛾𝑁𝑗+1 − 𝑗
𝛾𝑁𝑗] (1) 
𝑑𝑁1
𝑑𝑡
= −𝑘1𝑁1 + 𝑓[2
𝛽𝑁2 − 𝑁1] + 𝑘02
𝛾𝑁2 + 𝑘0
′ ∑ 𝑗𝛾𝑁𝑗
𝑗𝑚𝑎𝑥
𝑗=2
 (2) 
𝑑𝑁𝑗𝑚𝑎𝑥
𝑑𝑡
= 𝑘1(𝑗𝑚𝑎𝑥−1)
𝛼𝑁𝑗𝑚𝑎𝑥−1 − 𝑓𝑗𝑚𝑎𝑥
𝛽
𝑁𝑗𝑚𝑎𝑥 − 𝑘0𝑗𝑚𝑎𝑥
𝛾 𝑁𝑗𝑚𝑎𝑥  (3) 
An important limitation to this set of equations is the necessity to include a boundary condition at 
jmax.  Ideally, the system is unbounded at the upper end.  Due to the limitations of computing 
power however, jmax must be finite.  To that end, the boundary condition describe in Equation 3 
was chosen so that mass will be conserved in the system.  That is, no tumors disappear due to it.  
However, this means Njmax has the potential to grow in an unbounded fashion.  The error 
introduced by this boundary condition will be discussed further in the following text. 
The second order Runge-Kutta time stepping method used in the code is described by Equation 
4. 
𝑁𝑗
𝑛+1 = 𝑁𝑗
𝑛 +
Δ𝑡
2
(
𝑑𝑁𝑗
𝑛∗
𝑑𝑡
+
𝑑𝑁𝑗
𝑛
𝑑𝑡
) (4) 
Here, 
𝑑𝑁𝑗
𝑛
𝑑𝑡
 is 
𝑑𝑁𝑗
𝑑𝑡
 from Equation 1 calculated from the solution for the distribution at time t = nΔt, 
N
n
, and 
𝑑𝑁𝑗
𝑛∗
𝑑𝑡
 is calculated using the distribution obtained from Equation 5.  The formula for 
𝑑𝑁𝑗
𝑛∗
𝑑𝑡
 
is given explicitly in Equation 6.  It is convenient to note that the bracketed term in Equation 6 is 
simply the second derivative of Nj calculated using N
n
.  The compact formula for 
𝑑𝑁𝑗
𝑛∗
𝑑𝑡
 is shown 
in Equation 7. 
𝑁𝑗
𝑛∗ = 𝑁𝑗
𝑛 + Δ𝑡
𝑑𝑁𝑗
𝑛
𝑑𝑡
 (5) 
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𝑑𝑁𝑗
𝑛∗
𝑑𝑡
=
𝑑𝑁𝑗
𝑛
𝑑𝑡
+ Δ𝑡[𝑘1(𝑗 − 1)
𝛼 𝑑𝑁𝑗−1
𝑛
𝑑𝑡
− (𝑘1𝑗
𝛼 + 𝑓𝑗𝛽 + 𝑘0𝑗
𝛾)
𝑑𝑁𝑗
𝑛
𝑑𝑡
+ (𝑓(𝑗 + 1)𝛽 + 𝑘0(𝑗 +
1)𝛾)
𝑑𝑁𝑗+1
𝑛
𝑑𝑡
] (6) 
𝑑𝑁𝑗
𝑛∗
𝑑𝑡
=
𝑑𝑁𝑗
𝑛
𝑑𝑡
+ Δ𝑡
𝑑2𝑁𝑗
𝑛
𝑑𝑡2
 (7) 
Incorporating Equation 7 into Equation 4 gives Equation 8.  It is clear from comparing Equation 
7 to the Taylor series expansion of Nj(t+Δt) around t that the error accrued during a time step, ϵ, 
is O(Δt3) as stated in Equation 9.  The overall error for n time steps is the O(Δt2) as shown in 
Equation 10. 
𝑁𝑗
𝑛+1 = 𝑁𝑗
𝑛 + Δ𝑡
𝑑𝑁𝑗
𝑛
𝑑𝑡
+
Δ𝑡2
2
𝑑2𝑁𝑗
𝑛
𝑑𝑡2
 (8) 
𝜖 = 𝑁𝑗(𝑡 + Δ𝑡)−𝑁𝑗
𝑛+1 = 𝑂(Δ𝑡3) (9) 
𝑛 ⋅ 𝜖 = 𝑡𝑚𝑎𝑥𝑂(Δ𝑡
2) (10) 
 
Analysis Using Model Solutions: 
Since the Runge-Kutta method is an explicit discretization method, the size of the time step used 
must be limited to ensure the solution of the simulation does not become unstable. A useful 
method of determining appropriate time steps assumes a form of the exact solution to the system 
of equations.  The time steps that achieve a stable solution can then be obtained.   
One potential form for the solution of the system of equations is given by Equation 11.  Nj and t 
are specified as above and ηj is some function of the size coordinate j.  This form is related to the 
expected form of the equations when diffusion is the dominant process occurring, given in 
Equation 12.  Here, η is a function of the size coordinate. This solution will be useful when k1 
and f are equal. Since Equation 12 shrinks faster with increasing time than Equation 11, it is 
reasonable to assume that if Equation 11 is bounded for t > 0, then Equation 12 is also bounded. 
𝑁𝑗 = 𝑒
−
𝜂𝑗
𝑡  (11) 
𝑓(𝑡) =
𝐶
√𝑡
𝑒−
𝜂
𝑡  (12) 
Equation 13 is an equation showing the ratio of magnitudes of the solution over a time step.  The 
condition necessary to show the solution is bounded, described by Equation 14, is that the 
magnitude ratio is less than or equal to 1 as t approaches infinity.  It is obvious from Equation 13 
that this condition is satisfied as time is in the denominator of the two rightmost terms. 
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𝑁𝑗
𝑛+1
𝑁𝑗
𝑛 = 1 +
𝜂𝑗Δ𝑡
𝑡2
+
(𝜂𝑗
2−2𝜂𝑗𝑡)Δ𝑡
2
2𝑡4
 (13) 
𝑙𝑖𝑚
𝑡→∞
|
𝑁𝑗
𝑛+1
𝑁𝑗
𝑛 | ≤ 1 (14) 
Another model exact solution to the system is a traveling wave, Equation 15.  This solution is 
applicable when the convective term in the equation dominates diffusion as when k1 – f is very 
positive or very negative.  A similar analysis as above results in the magnitude ratio is shown in 
Equation 16.  The fact that the right hand side of Equation 16 is complex means that it is 
appropriate to convert it to amplitude-phase form as shown in Equation 17.  The amplitude and 
phase for the simulation solution are stated in Equations 18 and 19 respectively. 
𝑁𝑗 = 𝑒
−𝑖𝜂𝑗𝑡 (15) 
𝑁𝑗
𝑛+1
𝑁𝑗
𝑛 = 1 − 𝑖𝜂𝑗Δ𝑡 −
𝜂𝑗
2Δ𝑡2
2
 (16) 
𝑁𝑗
𝑛+1
𝑁𝑗
𝑛 = 𝐴𝑒
𝑖𝜃 (17) 
|
𝑁𝑗
𝑛+1
𝑁𝑗
𝑛 | = 𝐴 = 1 +
𝜂𝑗
4Δ𝑡4
4
 (18) 
𝜃 = 𝑡𝑎𝑛−1(
2𝜂𝑗Δ𝑡
𝜂𝑗
2Δ𝑡2−1
) = −𝜂𝑗Δ𝑡 +
5𝜂𝑗
3Δ𝑡3
6
+ 𝑂(𝜂𝑗
4Δ𝑡4) (19) 
Equation 18 shows that the solution method is unconditionally unstable as the magnitude ratio is 
always larger than 1.  Although it is unstable, the amplitude of the solution increases very 
slowly.  As long as the time step and frequency constant, ηj, are reasonable small, the amplitude 
will not be unduly large.   This is supported by the fact that the total error in amplitude for all 
time steps is third order, as depicted in Equation 20.  The total error in phase, Equation 21, is 
second order.  Assuming a positive ηj, Equation 19 shows that the phase of the simulation 
solution always lags behind that of the exact solution. 
𝑛 ⋅ 𝜖𝑎𝑚𝑝 = 𝑡𝑚𝑎𝑥𝑂(Δ𝑡
3) (20) 
𝑛 ⋅ 𝜖𝑝ℎ𝑎𝑠𝑒 = 𝑡𝑚𝑎𝑥𝑂(Δ𝑡
2) (21) 
Error Introduced through jmax Boundary Condition: 
As mentioned above, the jmax boundary condition introduces an error to the simulation.  This is 
because, in order to conserve mass, the boundary condition of use allows Njmax to grow in an 
unbounded fashion under certain conditions.  This is most prone to occur when the convection 
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terms in the equation move the tumor distribution to larger sizes.  Firstly, it should be noted that 
no error is introduced until t > (𝑗𝑚𝑎𝑥 − 𝑗0)Δt, where j0 is the largest tumor size with a non-zero 
probability at t = 0.  This is because the tumor distribution “information” travels only size step 
for each time step.  In other words, (𝑗𝑚𝑎𝑥 − 𝑗0)Δt is the smallest amount of time required for the 
tumors present at t = 0 to grow to the size jmax.  Secondly, the condition required for Njmax to 
grow is given by Equation 22. Since k1 and f the parameters of the model that are frequently 
varied, it is not reasonable to try to always satisfy Equation 22.  Finally, it is reasonable to state 
that the error introduced by the boundary condition is proportional to Njmax.  Therefore, Equation 
23 might describe a useful condition to gauge how simulation results are affected by the 
boundary condition.  If Njmax is small enough to satisfy Equation 23, it would be reasonable to 
assume the boundary condition error is negligible. 
𝑘1(𝑗𝑚𝑎𝑥 − 1)
𝛼 > 𝑓𝑗𝑚𝑎𝑥
𝛽
 (22) 
𝑁𝑗𝑚𝑎𝑥
∑ 𝑁𝑗
𝑗𝑚𝑎𝑥
𝑗=1
≤ 0.01 (23) 
Potential Improvements to Code: 
 Continuum approximation and change of size variable to accommodate larger tumor sizes 
 Higher order time discretization method or implicit time discretization to get a better 
quality solution 
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Results and Discussion 
It is important to see how tumors grow and shrink with different criteria applied. This research 
result can be used to apply better treatment options for cancer patients. There has been tumor 
modeling on one particular tumor throughout history but not many models available for multi 
size tumors. Iwata et al et al proposed a model based on multiple sizes of tumors which doesn’t 
only track one initial tumor but also accounts for a population of tumors and for the growth of 
metastasis [1]. Some of the variables involved in the calculation here are tabulated below along 
with their nomenclature. Arbitrary units can be used for certain parameters [1].  
 
k1 Effective rate of tumor growth 
f Effective death rate of tumor 
k10 Rate of tumor growth 
f0 Death rate of tumor 
k0 Rate of metastasis 
α  Exponential factor for growth term 
β  Exponential factor for death term 
γ  Exponential term for metastasis 
J Tumor size 
Nj Number of tumors of size j (population) 
jmax Maximum tumor size 
tmax Maximum time allowed for code to execute 
Cutoff j Tumor size after which chemotherapy is not effective 
                                                                                                                                                                
Table 1.  (Parameters used for calculation) 
 
Plots 
Here we have plotted different sets of variables and analyzed the resulting plots. A total of 38 
sets have been created each by changing one parameter from a previous runs. We will discuss a 
few key sets out of these 38 sets. A total of six different plots are generated by the Matlab code 
for each one of 38 sets. The first graph is the population distribution of different tumor sizes. The 
second graph combines three plots into 1 page, including average tumor size vs. time and total 
cell numbers at different times. The third plot verifies the initial condition values of the growth 
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rate and the death rate which we set equal to each other at t=0. The fourth plot shows if any 
metastasis rate has been utilized or not in an experiment at run. There is also a figure that shows 
distribution tumor number vs. tumor size at six time intervals. These time intervals can be set to 
analyze different curves. The next figure is important in terms of comparing the distribution 
curves on one plot at different times. It is helpful to show if a tumor travels to left or right. The 
last graph displays the time at which tumor size is maximum throughout the treatment. Initially 
different tumor sizes (ji) are tried along with varying numbers of tumors one by one. The 
maximum tumor size (jmax) that a tumor can reach is also adjusted along with tmax. There is a 
tumor cutoff size also added later on to reflect a limited influence of chemotherapy on tumor 
cells. All these variables can be changed to suit the experiment according to need. There are 7 
different plots for each set of parameter values. These curves will give a clear picture of the 
assumed model and help to recognize any deficiencies in the model.        
 
Effect of tmax 
To start with, we investigate the tumor distribution over different tmax. tmax is the maximum 
time that an experiment is carried on. We can continue the experiment over long periods of 
time to see the effects of chemotherapy and on different sizes of tumor. The values of 𝑘1(𝑗0) = 
𝑘10𝑗0
𝛼(𝑘1)
 and 𝑓 (𝑗0) = 𝑓0𝑗0
𝛽(𝑓)
are kept equal (0.05) and since 𝛼 and 𝛽are set to zero, k10and k1effective 
as well as f0and f effective are equal. There is no metastasis or cutoff size used in this trial. A few 
different values of tmax are used and results are compared below for two unique tmax values. 
 
 
Figure 1(A) (tmax = 7000) Figure 2(A) (tmax= 14000) 
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Figure 1(A) is a plot of tmax= 7000 units (set 3) and figure 2(A) is a plot of tmax= 14000 units (set 4). Both 
plots have initial tumor size of 100. The only difference between two plots is resulting scales. There is no 
other effect of tmax on distribution. That means applying chemotherapy for long period of time may 
result in shrinking of certain size tumors and growth of other if no metastasis process present. As it can 
be seen from figures above the population distribution of size 100 tumor is 0.015 at tmax =7000 while 
0.01 at tmax= 14000. Figure 1(B) and Figure 2(B) describes total number of tumors with respect to time 
for different tmax. Number of tumors starts to decrease because small tumors are killed off at later time 
as seen in Figure 1(B) and 2(B). Tumor numbers are affected at almost same rate at for both maximum 
times. Figure 1(C) and figure 2(C) shows the distribution vs. tumor size at different times. The plots are 
almost identical for the above values except for different time values. The importance of the plots will 
be explained further when the difference comes up in plots for the modified values of the variables.     
Figure 1(B) (tmax = 7000) Figure 2(B) (tmax= 14000) 
Figure 1(C) (tmax = 7000) Figure 2(C) (tmax= 14000) 
 
23 
 
 
Effect of the number of initial tumors 
Since we know the effect of tmax on population distribution, the next thing is to check effect of 
Ni(number of initial tumors) on the population. Here all the parameter values are kept to same as in the 
above example except the initial tumor numbers are changed. Two experiments are performed with two 
different initial tumor numbers. Below, plots are analyzed for 50 tumors of size 100 (set 5) as well as 100 
tumors of size 100 (set 6) for tmax= 7000 units. At long times, we expect the population distribution peak 
to be higher in the graph for large tumor size compare to small tumors due to bigger volume of large 
tumors. Bigger tumor volume takes more time to eradicate. And it will take relatively more time to 
reduce these tumors. This is verified by figure 3 and figure 4. For example, the peak is at 1.75 for 100 
initial tumors vs 0.85 for 50 initial tumors.   
 
 
 
Effect of initial tumor size 
Now we will check the influence of initial tumor size in this model. Again all the values are kept 
same as previous experiments. K1and f values are set 0.5 and metastasis and all the exponential 
parameters are neglected. The maximum tumor size that can be reached is set to 1000 units 
and maximum time is 7000 units. The experiment is performed for an initial tumor sizes of 200 
(set 9) and 500 (set 10) individually with one of each tumor. We expect the results to be similar 
to each other in terms of population distribution because we did not have any restriction of 
chemotherapy effectiveness. Both growth and chemo terms are set to equal values. Hence, 
population distribution is not dependent on initial tumor size. The results are shown in figure 5 
and figure 6. Although, the curve for tumor size 500 sits more toward right as expected, the 
distribution peaks are almost identical for both sizes. The difference, as one might notice is that 
total number of tumors decrease at an earlier time for initial tumor size of 200 than for initial 
Figure 3 (Ni(100)= 50)                                                         
Figure 4 (Ni(100)= 100) 
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tumor size of 500, because the left tail of the distribution reaches zero (tumor loss) earlier for 
the smaller tumor size.            
 
 
 
 
Figure 5 (ji = 200) 
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Adding cutoff size 
We began with one tumor of size ji= 100 and solved the equation 2 for the distribution plot. 
There was no restriction as to how effective chemotherapy is on tumor sizes. But there are 
some cases where literature indicates that the therapy only works for certain size of tumors. (4) 
It is worth to look at this cutoff size that introduces a maximum allowable tumor size below 
which tumors are controllable and above which therapy does not have any effects on cancer 
tumors. Once one finds out the outcome, one can devise a treatment accordingly. Different 
parameters have been applied below where there is no metastasis and k1 = f = 0.5 in figure 7 
(set 8) while k1 = f = 0.5 for j< 150 but f = 0 for j≥ 150 in figure 8 (set 28).    
Figure 6 (ji= 500) 
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Figure 7 and 8 represents distribution vs. tumor size at different times and figure 8 has cutoff 
size of 150 while no cutoff size in figure 7. In both systems, there is initially no net growth of 
tumors, but rather just a diffusive spread. The spread in figure 7 is broader means there are lots 
of small and big tumors present. However, at later times, tumors that are larger than 150 
appear in figure 8. The tumors do not get killed by therapy and this tail of the distribution grows 
rapidly. Hence, more tumors appear indicated by the long right tail in figure 8. These tumors 
grow fast and although number of tumor decreases due to the kill off of small tumors, the total 
number of tumor cells increases due to more volume in bigger tumors compared to model 
without cutoff size. This may be applicable for patients who exhibit some tumor reduction 
initially with therapy but suddenly start getting big tumors. This phenomenon is illustrated by 
the figures below.  
 
 
Figure 7(a) (k1 = f = 0.5) Figure 8(a) (f = 0 for j≥ 150) 
Figure 7(b) Figure 8(b) 
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K1vs.f 
So far the influence of various parameters on the distribution has been shown. Most important 
is to confirm how varying k1and f affects the model. Below is an example of k1= f = 0.5 vs.k1= 0.9 
and f = 0.45 for zero value of alpha, beta and gamma. Since exponential terms are zero in this 
example k1= k10and f = f0. For k1= f, figure 9 (set 9) shows the population distribution is 
symmetric about tumor size j = 200 but broadens about the same size at longer times. In 
contrast for k1>>f, as figure 10 (set 15) displays, the curve is not symmetric about the same 
tumor size, in fact the curve travels toward right side as it widens. Tumors keep growing 
symmetrically about growing tumor size with shifting to the right. This is due to rate of killing 
being smaller than tumor growth. Tumors are growing faster than the effect of chemotherapy.  
This kind of scenario is likely for a patient failing therapy treatment at long times while the 
cancer cell numbers keep growing.         
 
 
 
Figure 9 (k1= f = 0.5) 
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Adding α and β values separately 
The implication of different variables has been observed so far, now we can check the model by 
putting in various values of alpha and beta separately. Once we turn on alpha and beta the 
effective k1and effective f values will become j dependent because 𝑘1(𝑗0) = 𝑘10𝑗0
𝛼(𝑘1) and 𝑓 (𝑗0) 
=𝑓0𝑗0
𝛽(𝑓). So if alpha is higher than beta, then the effective growth surpasses effective death rate 
for j > j0 (the opposite happens for j < j0) and some tumors will become much larger and 
overtake chemotherapy’s effect. There will be lots of small and large tumors in the system and 
it broadens the distribution curve at longer time. On the other hand, if beta is bigger than 
alpha, the immunity term dominates and instead of getting a broader curve we will get 
narrower curve. This indicates there won’t be as many very small and very large tumors since 
therapy will kill most large tumors and small tumors will grow. Therefore, the curve does not 
broaden as much as the previous case at longer times. Figure 11 (set 34) and figure 12 (set 35) 
shows the distribution curves each for α>β and β>α respectively. Interestingly, the total number 
of tumors and number of cells starts to decrease at longer time for α>β as small tumors get 
killed off while number of tumors stays constant and number of cells start to increase at longer 
time for β>α. Initially the average tumor size decreases as small tumors are lost and then 
increases at later time as the large tumors enlarge for α>β while the average tumor size 
increases continuously for β>α. This is due to chemotherapy killing most of smaller tumors and 
Figure 10 (k1= 0.9, f = 0.45) 
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not many tumors grow back when considering β>α. inversely, when alpha is bigger than beta 
the growth term dominates for j > j0 and tumors with j > j0 keep getting bigger.         
 
 
 
 
 
 
The above graphs confirm that changing alpha and beta values affect the overall tumor bulk in 
terms of changes in tumor numbers. This situation arises when a patient has higher tumor 
growth compare to tumor death rate. Lots of little tumor as well as big tumors are grown in a 
patient’s body for high alpha. Turning on the exponential death term is equivalent to shooting 
up the tumor death rate with tumor size. Larger tumors are getting destroyed faster by therapy. 
Figure 11(A) and Figure 12(A) indicate this phenomenon. The number of tumors stays constant 
for alpha values turned on as compare to beta since beta can cause tumors to fully disappear. 
Figure 11(A) 
Figure 11 Figure 12 
Figure 12(A) 
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The number of tumor start to go down after some time due to the killing of infected cells for 
beta value turned on. The average tumor size increases after a certain time as expected for 
certain alpha values, while it decrease initially before increasing at certain time for beta value 
as seen from the above plot. 
 
 
Set k1 f k0 α  β  γ  ji 
No. of 
tumor jmax tmax 
Cutoff 
j 
Figure 1 5 0.05 0.05 0 0 0 0 100 50 1000 7000 N/A 
Figure 2 4 0.05 0.05 0 0 0 0 100 1 1000 14000 N/A 
Figure 3 5 0.05 0.05 0 0 0 0 100 50 1000 7000 N/A 
Figure 4 6 0.05 0.05 0 0 0 0 100 100 1000 7000 N/A 
Figure 5 9 0.5 0.5 0 0 0 0 200 1 1000 7000 N/A 
Figure 6 10 0.5 0.5 0 0 0 0 500 1 1000 7000 N/A 
Figure 7 8 0.5 0.5 0 0 0 0 100 1 1000 7000 N/A 
Figure 8 30 0.5 0.5 0 0 0 0 100 1 2000 2000 150 
Figure 9 9 0.5 0.5 0 0 0 0 200 1 1000 7000 N/A 
Figure 10 15 0.9 0.45 0 0 0 0 200 1 4000 5000 N/A 
Figure 11 34 0.01 0.14 0  1/2 0 0 200 1 1000 5000 N/A 
Figure 12 35 0.01 0.0007 0 0  1/2 0 200 1 1000 5000 N/A 
Table 2.  Simulation Parameter for Figures 
Further improvement 
The above model tested several variables but further work needs to be done regarding different 
ranges of variables. First of all, metastasis and gamma values have not yet been examined. It will 
be interesting to see how chemotherapy is affected by metastasis. Chemotherapy could have no 
effect at all if lots of tumors start to spread and get bigger. One can attempt to create a scenario 
where values of the growth term, the death term and the metastasis can be changed alternatively 
or individually by keeping one of the variables constant. There are many different combinations 
can be tried and tested to create a real life situation for cancer patients. There are different kinds 
of cancer with disparities about how the tumors behave for each type. Each patient also reacts 
differently to the treatment and model parameters can be fit accordingly. As stated before, above 
model is of the discrete tumor size type. For reality tumor sizes, we will have to continue to   
continuous tumor cases because in real life tumor numbers vary up to 10
10
.
 (2)
 Metastasis is also 
an important criterion that can be applied with continuous model. 
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Excel Sheet with different parameters: 
 
Set k1 f k0 α  β  γ  ji 
No. of 
tumor jmax tmax Cutoff j 
1 0.001 0.001 0 0 0 0 100 1 1000 7000 
2 0.01 0.01 0 0 0 0 100 1 1000 7000  
3 0.05 0.05 0 0 0 0 100 1 1000 7000  
4 0.05 0.05 0 0 0 0 100 1 1000 14000  
5 0.05 0.05 0 0 0 0 100 50 1000 7000  
6 0.05 0.05 0 0 0 0 100 100 1000 7000  
7 0.1 0.1 0 0 0 0 100 1 1000 7000  
8 0.5 0.5 0 0 0 0 100 1 1000 7000  
9 0.5 0.5 0 0 0 0 200 1 1000 7000  
10 0.5 0.5 0 0 0 0 500 1 1000 7000  
11 0.5 0.5 0 0 0 0 500 20 1000 7000  
12 0.9 0.9 0 0 0 0 100 1 1000 7000  
13 0.9 0.9 0 0 0 0 100 1 1500 10000  
14 0.9 0.45 0 0 0 0 100 1 5000 5000  
15 0.9 0.45 0 0 0 0 200 1 4000 5000  
16 0.9 0.45 0 0 0 0 300 1 4000 5000  
17 0.01 0.017 0 0.1 0 0 200 1 1000 5000 400  
18 0.01 0.141 0  1/2 0 0 200 1 1000 5000 400  
19 0.01 0.141 0.01  1/2 0 0 200 1 1000 5000 400  
20 0.01 0.141 0.005  1/2 0 0 200 1 1000 5000 400  
21 0.01 0.0007 0 0      1/2 0 200 1 1000 5000 400  
22 0.5 0.035 0 0      1/2 0 200 1 1000 5000 400  
23 0.9 0.064 0 0      1/2 0 200 1 1000 5000 400  
24 0.01 0.058 0  2/3  1/3 0 200 1 2000 2000 400  
25 0.005 0.029 0  2/3  1/3 0 200 1 2000 5000 400  
26 0.005 0.023 0  2/3  1/3 0 100 1 2000 5000 200  
27 0.5 0.5 0 0 0 0 100 1 2000 2000 100  
28 0.5 0.5 0 0 0 0 100 1 2000 2000 101  
29 0.5 0.5 0 0 0 0 100 1 2000 2000 120  
30 0.5 0.5 0 0 0 0 100 1 2000 2000 150  
31 0.5 0.5 0 0 0 0 100 1 2000 2000 200  
32 0.023/0.5 0.108/0.5 0 0.66667 0.33333 0 100 1 5000 3000  
33 0.01/0.017 0.017/0.017 0 0.1 0 0 200 1 1000 5000  set 17 
w/out 
cutoff  
34 0.01/0.14 0.14/0.14 0  1/2 0 0 200 1 1000 5000  set 18  
w/out 
cutoff 
35 0.01/0.01 0.0007/0.01 0 0  1/2 0 200 1 1000 5000  set 21 
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w/out 
cutoff  
36 0.9/0.9 0.063/0.9 0 0  1/2 0 200 1 1000 5000  set 23 
w/out 
cutoff  
37 0.01/0.342 0.058/0.342 0  2/3  1/3 0 200 1 2000 2000  set 24 
w/out 
cutoff  
38 0.01/0.342 0.058/0.342 0  2/3  1/3 0 200 1 2000 5000  set 24 
at 
longer 
time 
without 
cutoff 
size 
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Set 
k1 f k0 α  β  γ  ji 
No. of 
tumor jmax tmax Cutoff j 
4 0.05 0.05 0 0 0 0 100 1 1000 14000  
 
4.1: Tumor size vs Distribution at tmax for paramters in set 4 
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4.2: Time vs Number of cell and tumors for parameters in set 4 
 
4.3: Tumor size vs Metastasis rate for parameters in set 4 
 
4.4: Tumor Size vs rate for parameters in set 4 
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4.5: Tumor Size vs distribution for parameters in set 4 
 
 
 
4.6: Tumor Size vs distribution at different time for parameters in set 4 
 
37 
 
Set 
k1 f k0 α  β  γ  ji 
No. of 
tumor jmax tmax Cutoff j 
5 0.05 0.05 0 0 0 0 100 50 1000 7000  
 
 
 
5.1: Tumor size vs Distribution at tmax for paramters in set 5 
 
5.2: Time vs Number of cell and tumors for parameters in set 5 
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5.3: Tumor size vs Metastasis rate for parameters in set 5 
 
5.4: Tumor Size vs rate for parameters in set 5 
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5.5: Tumor Size vs distribution for parameters in set 5 
 
5.6: Tumor Size vs distribution for parameters in set 5 
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Set 
k1 f k0 α  β  γ  ji 
No. of 
tumor jmax tmax Cutoff j 
6 0.05 0.05 0 0 0 0 100 100 1000 7000 
  
 
6.1: Tumor size vs Distribution at tmax for paramters in set 6 
 
6.2 Time vs Number of cell and tumors for parameters in set 6 
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6.3: Tumor size vs Metastasis rate for parameters in set 6 
 
6.4: Tumor Size vs rate for parameters in set 6 
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6.5: Tumor Size vs distribution for parameters in set 6 
 
6.6: Tumor Size vs distribution for parameters in set 6 
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Set 
k1 f k0 α  β  γ  ji 
No. of 
tumor jmax tmax Cutoff j 
8 0.5 0.5 0 0 0 0 100 1 1000 7000 
 
 
 8.1: Tumor size vs Distribution at tmax for paramters in set 8 
 
8.2: Time vs Number of cell and tumors for parameters in set 8 
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8.3: Tumor size vs Metastasis rate for parameters in set 8 
 
 
 
8.4: Tumor Size vs rate for parameters in set 8 
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8.5: Tumor size vs distribution for parameters in set 8. 
 
8.6: Tumor size vs distribution at different times for parameter in set 8. 
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Set 
k1 f k0 α  β  γ  ji 
No. of 
tumor jmax tmax Cutoff j 
9 0.5 0.5 0 0 0 0 200 1 1000 7000 
  
 
9.1: Tumor size vs Distribution at tmax for paramters in set 9 
 
9.2: Time vs Number of cell and tumors for parameters in set 9 
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9.3: Tumor size vs Metastasis rate for parameters in set 9 
 
9.4: Tumor Size vs Distribution for parameters in set 9 
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9.5: Tumor Size vs rate for parameters in set 9 
 
9.6: Tumor Size vs Distribution for parameters in set 9 
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Set 
k1 f k0 α  β  γ  ji 
No. of 
tumor jmax tmax Cutoff j 
10 0.5 0.5 0 0 0 0 500 1 1000 7000 
  
 
10.1: Tumor size vs Distribution at tmax for paramters in set 10 
 
10.2: Time vs Number of cell and tumors for parameters in set 10 
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10.3: Tumor size vs Metastasis rate for parameters in set 10 
 
10.4: Tumor Size vs rate for parameters in set 10 
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10.5: Tumor Size vs distribution for parameters in set 10 
 
 
10.6: Tumor Size vs distribution for different time for parameters in set 10 
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Set 
k1 f k0 α  β  γ  ji 
No. of 
tumor jmax tmax Cutoff j 
15 0.9 0.45 0 0 0 0 200 1 4000 5000 
  
 
15.1: Tumor size vs Distribution at tmax for paramters in set 15 
 
15.2: Time vs Number of cell and tumors for parameters in set 15 
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15.3: Tumor size vs Metastasis rate for parameters in set 15 
 
15.4: Tumor Size vs rate for parameters in set 15 
 
54 
 
 
15.5: Tumor Size vs distribution for parameters in set 15 
 
 
15.6: Tumor Size vs distribution for parameters in set 15 
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Set 
k1 f k0 α  β  γ  ji 
No. of 
tumor jmax tmax Cutoff j 
30 0.5 0.5 0 0 0 0 100 1 2000 2000 150 
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Set 
k1 f k0 α  β  γ  ji 
No. of 
tumor jmax tmax Cutoff j 
34 0.01/0.14 0.14/0.14 0  1/2 0 0 200 1 1000 5000 
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Set 
k1 f k0 α  β  γ  ji 
No. of 
tumor jmax tmax Cutoff j 
35 0.01/0.01 
0.0007/0.0
1 0 0  1/2 0 200 1 1000 5000 35 
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